Search · resolved
Which podcasts are discussing AMGN?
6 ATTRIBUTED IDEAS · 6 EPISODES · 5 SHOWS
The shows
The Compound and Friends
Barron's Streetwise
CNBC Fast Money
WSJ What's News
Yet Another Value Podcast
Where the discussion went deepest
3 AUG1W AGOCNBC FAST MONEY · 26:00
Amgen poised for a technical breakout into earnings
“The chart analysis argued Amgen is set up for a bullish technical breakout ahead of earnings, with a symmetrical recovery pattern and a long-term uptrend pointing to further upside.”
Software Leading a Market Rally… And What To Expect from Yen Intervention. 8/3/26
In depth · 4/5Verify in source →
23 MAR23 MARYET ANOTHER VALUE PODCAST · 28:00
OX40 competitor failures create vacuum for Nectar
“The guest argued that the efficacy collapse and safety issues (Kaposi's sarcoma) of competing OX40-class drugs from Amgen and Sanofi have created a massive market-share vacuum for Nectar's ResPeg.”
Adam May on investing in biotech $NKTR $ABVX · with Adam May
In depth · 4/5Verify in source →
1 MAY1 MAYTHE COMPOUND AND FRIENDS · 25:00
8 AUG4D AGOWSJ WHAT'S NEWS · 3:00
Amgen lifts forecast despite obesity drug halt
“The report argued Amgen raised its full-year forecast and beat revenue expectations significantly, driven by strong sales of existing treatments, despite ending development on an obesity drug.”
What’s News in Markets: Dow Hits 54,000, Chip Stocks Waver, SpaceX Rebounds
Notable comment · 2/5Verify in source →
31 JUL2W AGOBARRON'S STREETWISE · 27:00
17 JUL4W AGOTHE COMPOUND AND FRIENDS · 1:15:55
Amgen monetizes research on osteoporosis reversal
“The guest highlighted Amgen's commercialization of a novel drug discovered via research at the Stowers Institute that reverses bone decay in osteoporosis.”
You’re About to See the Real AI Winners Stand Up
Notable comment · 2/5Verify in source →
The weekly signal
Get a weekly digest of what podcasts said about your watchlist.
Pick a few tickers. Once a week we send the most-discussed ideas across finance podcasts, attributed and linked so you can verify. No noise, no advice.
Double opt-in: we’ll email you to confirm before anything else. We store your email and chosen tickers only to send this digest. Nothing else, and we never share them.